At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 20 target
Drug / intervention
Lithium carbonatedrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Three Month, Open-label, Single-arm Trial Evaluating the Safety and Pharmacokinetics of Oral Lithium in Patients Diagnosed With Chronic Spinal Cord Injury
In Brief
A Phase 1 clinical trial evaluating Lithium carbonate for Spinal Cord Injuries. Completed, enrolled 20 participants across 1 site.
Detailed Summary
The current study is a phase I open-label clinical trial to examine plasma levels after oral lithium treatments in 20 subjects with chronic spinal cord injury. The subjects will receive standard doses of oral lithium used in treatment of manic depression. The goal of the trial is to show feasibility and safety of maintaining plasma levels of 0.6 mmol/L to 1.2 mmol/L for six weeks in subjects with chronic spinal cord injury.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSpinal Cord Injuries
CountriesChina
CollaboratorsChina Spinal Cord Injury Network
Timeline
Phase 1CompletedFinished
200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedFeb 2007
Enrollment StartSep 2007
Primary CompletionJan 2010
TodayJul 2026
First PostedFeb 5, 2007
Enrollment StartSep 1, 2007
Primary CompletionJan 1, 2010
TodayJul 2, 2026
Enrollment to primary: 2.3 yearsPosted 19.4 years ago
Interventions
Lithium carbonatedrug